Stem Cell-Derived Enteric Neural Crest Cells for Hirschsprung Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The in vitro derivation of human enteric nervous system (ENS) lineages from stem cells has remained elusive, limiting the understanding of ENS development and the availability of suitable models for gastrointestinal disorders like Hirschsprung's disease.
Innovation Solution
A method involving the use of specific signaling pathway modulators, such as inhibitors of TGFβ/Activin-Nodal signaling and activators of Wnt signaling, combined with molecules that induce vagal neural crest patterning, to differentiate stem cells into enteric neural crest lineage cells, followed by maturation conditions to produce enteric neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional differentiation protocols are used, then general neural crest cells can be derived, but specific enteric neural crest lineage cells cannot be obtained
Solution Approach 1:
The patent applies local quality by introducing spatial and temporal gradients of signaling molecules (Wnt, BMP, FGF) at specific concentrations and time points during differentiation. This creates localized microenvironments that guide stem cells toward enteric neural crest lineage specifically, rather than general neural crest differentiation. The staged protocol with distinct phases (neural induction, neural crest specification, enteric lineage commitment) ensures precise local control over cell fate decisions.
Solution Approach 2:
The patent systematically changes key parameters including Wnt signaling activation timing, BMP inhibition duration, FGF concentration gradients, and oxygen tension levels to drive differentiation toward enteric neural crest. By dynamically adjusting these parameters in a staged protocol, the method achieves precise lineage specification that conventional static protocols cannot accomplish.
2Loss of information
If in vitro differentiation methods are developed, then understanding of ENS development improves, but suitable models for GI disorders remain unavailable
Solution Approach 1:
The patent employs preliminary action by first establishing a robust in vitro differentiation protocol that reliably produces enteric neural crest cells and neurons before attempting disease modeling. The method pre-establishes control cell lines with known genotypes and validates differentiation efficiency and cell identity markers before introducing disease-specific genetic modifications or primary patient cell derivations.
Solution Approach 2:
The patent creates in vitro copies of in vivo enteric nervous system development and pathology. By differentiating stem cells into ENS lineages that mimic fetal gut development, and by introducing disease-causing mutations or using patient-derived iPSCs, the method produces reliable disease models that replicate human ENS disorders including Hirschsprung's disease, allowing study of pathological mechanisms without requiring surgical tissue samples.
3Ease of operation
If primary tissue access is limited, then direct study of ENS disorders is constrained, but stem cell-derived models can overcome this limitation
Solution Approach 1:
The patent uses stem cells as an intermediary to bridge the gap between limited primary tissue access and the need for ENS disease study. Patient-derived iPSCs or engineered stem cell lines serve as renewable intermediaries that can be differentiated into enteric neural crest and neurons, providing unlimited access to disease-relevant cell types without requiring repeated surgical biopsies or fetal tissue donation.
Solution Approach 2:
The patent enables self-service by establishing self-renewing stem cell lines that can autonomously differentiate into enteric neural crest lineage cells. Once the differentiation protocol is established, the system serves itself by generating unlimited supplies of disease-model cells from a single patient's cells or a validated stem cell line, eliminating the need for continuous primary tissue collection.
Data Source
AI summary
The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells into enteric neural crest lineage cells, and enteric neural crest lineage cells by such methods. The presently disclosed subject matter also provides for uses of such enteric neural crest lineage cells for preventing and/or treating enteric nervous system disorders (e.g, Hirschsprung's disease), and for screening compounds suitable for preventing and/or treating enteric nervous system disorders (e.g., Hirschsprung's disease).